Overview
Basic Science:
-Germline and somatic genetic changes in breast cancer.
Translational:
-Identification and management of individuals and families with hereditary cancer risk.
-Communication of cancer risk information to individuals and families.
-Breast cancer prevention.
-Optimizing management of early breast cancer.
-Treatment of metastatic breast cancer
Clinically, Dr. Marcom works as a medical oncologist in the multidisciplinary breast cancer clinic. He participates in clinical trials investigating new chemotherapeutic and biologic treatments.
-Germline and somatic genetic changes in breast cancer.
Translational:
-Identification and management of individuals and families with hereditary cancer risk.
-Communication of cancer risk information to individuals and families.
-Breast cancer prevention.
-Optimizing management of early breast cancer.
-Treatment of metastatic breast cancer
Clinically, Dr. Marcom works as a medical oncologist in the multidisciplinary breast cancer clinic. He participates in clinical trials investigating new chemotherapeutic and biologic treatments.
Current Appointments & Affiliations
Adjunct Professor in the Department of Medicine
·
2021 - Present
Medicine, Medical Oncology,
Medicine
Member of the Duke Cancer Institute
·
1989 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Returning Individual-Level Urgent or Emergent Research Results to Participants: The Project Baseline Health Study Experience.
Journal Article Am J Med Open · June 2025 BACKGROUND: Returning results to research participants is increasingly recognized as an ethical mandate, yet little is known about best practices to optimally communicate urgent or emergent results. METHODS: We describe the development of and experience wi ... Full text Link to item CiteA Phase I Trial of Alpelisib Combined With Capecitabine in Patients With HER2-Negative Metastatic Breast Cancer.
Journal Article Clin Breast Cancer · December 2024 BACKGROUND: Alpelisib is an oral α-specific class I PI3K inhibitor approved in combination with fulvestrant for the treatment of PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) metastatic breast can ... Full text Link to item CiteAdjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT.
Journal Article J Clin Oncol · November 2024 PURPOSE: Long-term outcomes of patients with stage I human epidermal growth factor receptor 2 (HER2)-positive breast cancer receiving adjuvant trastuzumab emtansine (T-DM1) remain undefined, and prognostic predictors represent an unmet need. METHODS: In th ... Full text Link to item CiteRecent Grants
TBCRC 041 Randomized Phase II Trial to Evaluate Alisertib Alone or Combined with Fulvestrant in Women with Advanced, Hormone-Receptor Positive (HR+) Breast Cancer
Clinical TrialPrincipal Investigator · Awarded by Mayo Clinic · 2019 - 2025Kastan Gray Foundation Project
ResearchResearcher · Awarded by Gray Foundation · 2017 - 2024TBCRC48 A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients with Germline or Somatic Mutations in DNA Repair Genes "Olaparib Expanded"
Clinical TrialPrincipal Investigator · Awarded by Johns Hopkins University · 2018 - 2023View All Grants
Education, Training & Certifications
Baylor University ·
1989
M.D.